Call Today: 800-889-3898
Contact us for free information or to start a free case review.
Bayer AG announced yesterday that it was halting a clinical trial of its heart surgery drug Trasylol because of evidence of an increased risk of death from hemorrhaging.
Trasylol , generically known as aprotinin, gained approval by the Food and Drug Administration in 1993 for preventing blood clots in certain heart bypass patients. Over the past year, however, the drug's safety has come into question.
Accumulating Data
Data from previous studies has suggested that Trasylol raises the risk of kidney damage, stroke, and death. On Thursday, the FDA posted a statement on its website warning doctors of “accumulating data suggesting” an increased death risk.
Last year, a warning was added to the drug's label to limit its use to patients with a higher risk of blood loss during heart surgery. Despite its risks the drug has remained on the market, though an FDA advisory panel last month urged Bayer to conduct a rigorous clinical trial.
Bayer knew about the possible increased risk of death associated with its drug, and admitted to withholding a study of nearly 70,000 hospital records suggesting that risk. The company blamed the failure to disclose the study on a “regrettable human error.”
(Source: New York Times online)
Injured by Trasylol? You may be entitled to compensation. Contact an experienced defective drug attorney near you today to learn more about your legal rights.
Copyright © 2001 - 2012 Online Lawyer Source
ATTORNEY ADVERTISEMENT—Thank you for your visit. The content published on this website was not written by medical professionals and should not, at any point, be mistaken for medical advice. Furthermore, the information on this site is intended for educational purposes only and should never interfere with a patient/site visitor and his or her healthcare provider. In addition, viewing the content on this website, requesting additional information, or transmitting information through a contact form should never be considered the formation of an attorney-client relationship. The material published on this site is general and may not apply to your specific circumstances. Every case comes with its own set of unique circumstances; past success discussed on this site does not guarantee future performance. Information found on this website should not be used as incentive to act without seeking counsel from a professional. For more information, please read our disclaimer.